Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Swiss firm actelion to buy U.S. biotech
November 27, 2006
| A version of this story appeared in
Volume 84, Issue 48
Swiss biopharmaceutical firm Actelion has entered a definitive agreement to acquire CoTherix, a Brisbane, Calif., biopharma company, for about $420 million. CoTherix markets Ventavis, the only approved inhaled drug for the treatment of pulmonary arterial hypertension (PAH) in the U.S. CoTherix had been investigating combined use of Ventavis and Tracleer, an oral PAH treatment marketed by Actelion. In another deal in the same market, Gilead Sciences recently spent $2.5 billion to buy Myogen, which is developing the PAH treatment ambrisentan.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter